Jose A. Parra-Todoli
Valencia, VC, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 25 publications
Value of nailfold capillaroscopy in the classification of the systemic sclerosis pattern.
Journal: Medicina clinica
Published: January 02, 2026
Decreasing prevalence and cumulative incidence of scleroderma renal crisis over time: associated factors identified from the RESCLE registry.
Journal: Rheumatology (Oxford, England)
Published: April 21, 2025
CAPI-Detect: machine learning in capillaroscopy reveals new variables influencing diagnosis.
Journal: Rheumatology (Oxford, England)
Published: August 09, 2024
Capi-score: a quantitative algorithm for identifying disease patterns in nailfold videocapillaroscopy.
Journal: Rheumatology (Oxford, England)
Published: November 29, 2023
Nailfold videocapillaroscopy patterns in systemic sclerosis: implications for cutaneous subsets, disease features and prognostic value for survival.
Journal: Clinical and experimental rheumatology
Published: May 08, 2023
Dysimmunity in common variable immunodeficiency is associated with alterations in oral, respiratory, and intestinal microbiota.
Journal: Clinical immunology (Orlando, Fla.)
Published: March 06, 2023
External clinical validation of automated software to identify structural abnormalities and microhaemorrhages in nailfold videocapillaroscopy images.
Journal: Clinical and experimental rheumatology
Published: December 01, 2022
Left ventricular diastolic dysfunction in systemic sclerosis: Clinical, immunological and survival differences in the Spanish RESCLE registry.
Journal: Seminars in arthritis and rheumatism
Published: March 07, 2022
The challenge of comprehensive nailfold videocapillaroscopy practice: a further contribution.
Journal: Clinical and experimental rheumatology
Published: August 03, 2021
The incidence rate of pulmonary arterial hypertension and scleroderma renal crisis in systemic sclerosis patients with digital ulcers on endothelin antagonist receptors (ERAs) and phosphodiesterase-5 inhibitors (PDE5i).
Journal: Rheumatology (Oxford, England)
Published: March 07, 2020
Last Updated: 09/26/2026